Kebele Elimination of Trachoma for Ocular Health
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Nov 3, 2017
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Kebele Elimination of Trachoma for Ocular Health trial is studying a new approach to eliminate trachoma, a serious eye infection that can lead to blindness. This trial will compare two strategies for distributing a medication called azithromycin: one is a targeted distribution plan that aims to reach specific groups of people, and the other follows the standard World Health Organization (WHO) recommendation of distributing the medication once a year to everyone in the community.
Anyone living in the participating communities can join the trial, as the study includes all individuals who are eligible for the annual distribution of azithromycin according to WHO guidelines. The main requirement to participate is that individuals must agree to be part of the study. If you join, you can expect to receive treatment based on one of the two strategies being tested. This trial is currently recruiting participants of all ages and genders, and it aims to find the most effective way to eliminate trachoma in these areas, which could significantly improve eye health for many people.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All individuals in all communities will be eligible for annual mass azithromycin distribution per WHO guidelines.
- Exclusion Criteria:
- • Those who do not consent.
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Bahir Dar, , Ethiopia
Patients applied
Trial Officials
Tom M Lietman, MD
Principal Investigator
University of California, San Francisco
Hadley Burroughs, MSPH
Study Director
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials